Editorial: Inborn Errors of Immunity and Mucosal Immunity

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 May 25

PMID 37228613

Authors

Elena Wen-Yuan Hsieh

Scott B Snapper

Edwin F de Zoeten

Affiliations

Soon will be listed here.

References

Uhlig H, Schwerd T . From Genes to Mechanisms: The Expanding Spectrum of Monogenic Disorders Associated with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 22(1):202-12. DOI: 10.1097/MIB.0000000000000614. View

Monteleone G, Neurath M, Ardizzone S, Di Sabatino A, Fantini M, Castiglione F . Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015; 372(12):1104-13. DOI: 10.1056/NEJMoa1407250. View

Wouters C, Maes A, Foley K, Bertin J, Rose C . Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J. 2014; 12:33. PMC: 4136643. DOI: 10.1186/1546-0096-12-33. View

Proell M, Riedl S, Fritz J, Rojas A, Schwarzenbacher R . The Nod-like receptor (NLR) family: a tale of similarities and differences. PLoS One. 2008; 3(4):e2119. PMC: 2323615. DOI: 10.1371/journal.pone.0002119. View

Ogura Y, Bonen D, Inohara N, Nicolae D, Chen F, Ramos R . A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411(6837):603-6. DOI: 10.1038/35079114. View

Vardi I, Chermesh I, Werner L, Barel O, Freund T, McCourt C . Monogenic Inflammatory Bowel Disease: It's Never Too Late to Make a Diagnosis. Front Immunol. 2020; 11:1775. PMC: 7509434. DOI: 10.3389/fimmu.2020.01775. View

Boirivant M, Pallone F, Di Giacinto C, Fina D, Monteleone I, Marinaro M . Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006; 131(6):1786-98. DOI: 10.1053/j.gastro.2006.09.016. View

Collen L, Kim D, Field M, Okoroafor I, Saccocia G, Whitcomb S . Clinical Phenotypes and Outcomes in Monogenic Versus Non-monogenic Very Early Onset Inflammatory Bowel Disease. J Crohns Colitis. 2022; 16(9):1380-1396. PMC: 9455789. DOI: 10.1093/ecco-jcc/jjac045. View

Pazmandi J, Kalinichenko A, Ardy R, Boztug K . Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol Rev. 2018; 287(1):162-185. PMC: 7379380. DOI: 10.1111/imr.12726. View

10.

Nambu R, Warner N, Mulder D, Kotlarz D, McGovern D, Cho J . A Systematic Review of Monogenic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2021; 20(4):e653-e663. PMC: 8448782. DOI: 10.1016/j.cgh.2021.03.021. View

11.

Ouahed J, Spencer E, Kotlarz D, Shouval D, Kowalik M, Peng K . Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis. 2019; 26(6):820-842. PMC: 7216773. DOI: 10.1093/ibd/izz259. View

12.

Muise A, Snapper S, Kugathasan S . The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology. 2012; 143(2):285-8. DOI: 10.1053/j.gastro.2012.06.025. View

13.

Monteleone G, Stolfi C, Marafini I, Atreya R, Neurath M . Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?. Mol Diagn Ther. 2022; 26(5):477-481. PMC: 9411088. DOI: 10.1007/s40291-022-00606-1. View

14.

Ligumsky M, Simon P, Karmeli F, Rachmilewitz D . Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. Gut. 1990; 31(6):686-9. PMC: 1378497. DOI: 10.1136/gut.31.6.686. View

15.

Conrad M, Kelsen J . Genomic and Immunologic Drivers of Very Early-Onset Inflammatory Bowel Disease. Pediatr Dev Pathol. 2019; 22(3):183-193. PMC: 6942488. DOI: 10.1177/1093526619834807. View

16.

Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D . Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018; 142(6):1932-1946. PMC: 6215742. DOI: 10.1016/j.jaci.2018.02.055. View

17.

Monteleone G, Kumberova A, Croft N, McKenzie C, Steer H, MacDonald T . Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001; 108(4):601-9. PMC: 209401. DOI: 10.1172/JCI12821. View

18.

Matsuda T, Kambe N, Ueki Y, Kanazawa N, Izawa K, Honda Y . Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the mutation. Ann Rheum Dis. 2020; 79(11):1492-1499. DOI: 10.1136/annrheumdis-2020-217320. View

19.

Di Fusco D, Dinallo V, Marafini I, Figliuzzi M, Romano B, Monteleone G . Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease. Front Pharmacol. 2019; 10:305. PMC: 6450224. DOI: 10.3389/fphar.2019.00305. View

20.

Hugot J, Chamaillard M, Zouali H, Lesage S, Cezard J, Belaiche J . Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411(6837):599-603. DOI: 10.1038/35079107. View